medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2013, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2013; 60 (1)

Subclinical inflammation in 18,310 blood donors smoker and nonsmokers: The white blood cell count as inflammation marker

Vences-Avilés MA, Gama-Valdez L

Language: Spanish
References: 30
Page: 33-42
PDF size: 123.74 Kb.


ABSTRACT

Background: Smoking has been associated with low-grade systemic inflammation, a known risk factor for cardiovascular disease (CVRF). This state is reflected in elevated white blood cell count (WBC). Objective.: Analyze the relationship between smoking and WBC in blood donors, men and women, of several age groups and analyze the relationship between WBC and others traditional cardiovascular risk factors. Material and methods: Prospective cross-sectional study in 15,601 men and 2,709 women aged between 18 and 65 years. Data analyzed were smoking state and smoking intensity, other cardiovascular risk factors and WBC count. Results: 350 women (12.9%) and 5,091 (32.6%) men were smokers. In both genders, the average count of WBC/mm3 was higher in smokers than in nonsmokers (p = 0.001). WBC remains high in smokers of all age groups, from 18 to 65 years. Analysis of variance showed significant differences in WBC count according to the smoking intensity: nonsmoking versus smoking 1-4 cigarettes/day or ≥ 5 years smoking duration versus smoking ≥ 5 cigarettes/day for ≥ 5 years in men and women (p = 0.001). In bivariate analyses, others traditional cardiovascular risk factors are also associated to increased WBC count. Conclusions: Smoking was associated with elevated WBC, which remains significant in all age groups studied and in both genders. We found that a dose-response relationship exist between smoking intensity and WBC count.


REFERENCES

  1. World Health Organization. Global status report on noncommunicable diseases. Geneva: WHO; 2011.

  2. World Health Organization. Report on the global tobacco epidemic, 2008: the MPOWER package. Geneva: WHO. ISBN: 978 92 4 159628 2. [junio 20]. Available in: http://www.who.int/tobacco/mpower/gtcr_download/en/index.html (Access:June,20th 2012).

  3. Organización Panamericana de la Salud; Instituto Nacional de Salud Pública (MX). Encuesta Global de Tabaquismo en Adultos. México 2009. Cuernavaca, México: INSP/OPS; 2010. Disponible en: www.who.int/tobacco/surveillance/gats_rep-mexico.pdf

  4. Balanescu S, Calmac L, Constantinescu D, Marinescu M, Onut R et al. Systemic inflammation and early atheroma formation: Are they related? Maedica (Buchar) 2010; 5 (4): 292-301.

  5. Nicklas BJ, Brinkley TE. Exercise training as a treatment for chronic inflammation in the elderly. Exerc Sport Sci Rev 2009; 37 (4): 165-70.

  6. Danesh J, Collins R, Appleby P, Peto R. Fibrinogen, C-reactive protein, albumin or white cell count: Meta-analyses of prospective studies of coronary heart disease. JAMA 1998; 279: 1477-1482.

  7. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-235.

  8. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax 1987; 42 (4): 241-249.

  9. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17 (10): 2167-2176.

  10. Noble RC, Penny BB. Comparison of leukocyte count and function in smoking and nonsmoking young men. Infect Immun 1975; 12 (3): 550-555.

  11. Burney SW, Bonus L. Cross-sectional assessment of laboratory variables in a healthy male population. II. Cigarette smoking and laboratory values. Aging Hum Dev 1972; 3: 89-94.

  12. Corre F, Lellouch J, Schwartz D. Smoking and leukocyte counts. Results of an epidemiologic study. Lancet 1971; 2: 632-634.

  13. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279 (18): 1477-1482.

  14. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107 (3): 499-511.

  15. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF et al. Women’s Health Initiative Research Group. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: The Women’s Health Initiative Observational Study. Arch Intern Med 2005; 165 (5): 500-508.

  16. Tamakoshi K, Toyoshima H, Yatsuya H, Matsushita K, Okamura T et al. NIPPON DATA90 Research Group. White blood cell count and risk of all-cause and cardiovascular mortality in nationwide sample of Japanese-results from the NIPPON DATA90. Circ J 2007; 71 (4): 479-485.

  17. Smith MR, Kinmonth AL, Luben RN, Bingham S, Day NE et al. Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. Atherosclerosis 2003; 169 (2): 331-337.

  18. Fiz JA, Morera J, Monsonis JV, Calvo A, Vazquez A, Espinal A et al. Systemic inflammation in 222.841 healthy employed smokers and nonsmokers: white blood cell count and relationship to spirometry. Tob Induc Dis 2012; 10 (1): 7. [Epub ahead of print]

  19. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic diseases. JAMA 1987; 257 (17): 2318-2324.

  20. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.

  21. Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P. Association between circulating white blood cell count and cancer mortality: A population-based cohort study. Arch Intern Med 2006; 166 (2): 188-194.

  22. Schwartz J, Weiss ST. Host and environmental factors influencing the peripheral blood leukocyte count. Am J Epidemiol 1991; 134: 1402-1409.

  23. Asthana A, Johnson HM, Piper ME, Fiore MC, Baker TB, Stein JH. Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers. Am Heart J 2010; 160 (3): 458-463.

  24. Sprague BL, Trentham-Dietz A, Klein BE, Klein R, Cruickshanks KJ et al. Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2008; 17 (10): 2714-2722.

  25. Huang ZS, Chien KL, Yang CY, Tsai KS, Wang CH. Peripheral differential leukocyte counts in humans vary with hyperlipidemia, smoking, and body mass index. Lipids 2001; 36 (3): 237-245.

  26. Moradi S, Kerman SR, Rohani F, Salari F. Association between diabetes complications and leukocyte counts in Iranian patients. J Inflamm Res 2012; 5: 7-11.

  27. Holz T, Thorand B, Döring A, Schneider A, Meisinger C et al. Markers of inflammation and weight change in middle-aged adults: results from the prospective MONICA/KORA S3/F3 study. Obesity (Silver Spring) 2010; 18 (12): 2347-2353.

  28. Dietrich M, Jialal I. The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev 2005; 63 (1): 22-28.

  29. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S et al. Coronary plaque regression and lifestyle modification in patients treated with pravastatin. Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol. Circ J 2010; 74 (5): 954-961.

  30. Tani S, Nagao K, Anazawa T, Kawamata H, Furuya S et al. Association of leukocyte subtype counts with coronary atherosclerotic regression following pravastatin treatment. Am J Cardiol 2009; 104: 464-469.




2020     |     www.medigraphic.com